<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01787474</url>
  </required_header>
  <id_info>
    <org_study_id>2012-0079</org_study_id>
    <secondary_id>NCI-2014-00883</secondary_id>
    <secondary_id>NCI-2014-00841</secondary_id>
    <secondary_id>2012-0079</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT01787474</nct_id>
  </id_info>
  <brief_title>Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21-Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of donor natural kill cells and
      to see how well they work in treating patients with acute myeloid leukemia that does not
      respond to treatment (refractory) or has come back after a period of improvement (relapsed).
      Giving natural killer cells after high dose chemotherapy may boost the patient's immune
      system by helping it see the remaining cancer cells as not belonging in the patient's body
      and causing it to destroy them (called graft-versus-tumor effect).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the safety, feasibility, and maximum tolerated dose of membrane-bound
      interleukin 21 (mbIL21)-expanded haploidentical natural killer (NK) cells after induction
      chemotherapy with fludarabine (fludarabine phosphate), cytarabine, and filgrastim-sndz,
      Zarxio (filgrastim-sndz) (G-CSF) (FLAG).

      SECONDARY OBJECTIVES:

      I. Determine the persistence of adoptively-transferred expanded NK cells. II. Determine the
      immunophenotype and function of expanded NK cells. III. Determine the overall response of
      acute myeloid leukemia (AML) to this regimen.

      IV. Correlate NK cell persistence, phenotype, and function with overall response.

      V. Estimate the rate at which patients receiving this regimen are able to go to transplant.

      OUTLINE: This is a phase I, dose-escalation study of membrane-bound interleukin-21-expanded
      haploidentical natural killer cells followed by a phase II study.

      Patients receive filgrastim-sndz subcutaneously (SC) once daily (QD) beginning on day -7 and
      continuing until absolute neutrophil counts (ANC) are equal or over 1000. Patients also
      receive fludarabine phosphate intravenously (IV) over 30 minutes and approximately 4 hours
      later followed by cytarabine IV over 1 hour on days -6 to -2 (days -6 to -3 for patients over
      age 60). Beginning 2-7 days after the last dose of fludarabine phosphate and cytarabine,
      patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells
      IV over 30 minutes thrice weekly for 3 doses over 4 days (Monday-Thursday only).

      After completion of study treatment, patients are followed up for 56 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2014</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of natural killer (NK) cells, defined as the highest dose level at which no more than 2 patients in a 6-patient cohort experience a dose limiting toxicity during treatment</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission rate (CR)</measure>
    <time_frame>Day 56 following infusion of the NK cells</time_frame>
    <description>Estimated with Kaplan-Meier estimator and tabulated with 95% confidence intervals. Cox proportional hazards regression will be used to model CR as a function of NK cell dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK-cell numerical expansion in vivo defined as an absolute circulating donor-derived NK cell count that increases above the post-infusion level</measure>
    <time_frame>Up to day 56</time_frame>
    <description>Proportion of patients with successful in vivo NK-cell expansion estimated with a 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to transplantation (TTT)</measure>
    <time_frame>Up to day 56</time_frame>
    <description>Estimated with Kaplan-Meier estimator and tabulated with 95% confidence intervals. Cox proportional hazards regression will be used to model TTT as a function of NK cell dose.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (NK cells)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive filgrastim-sndz SC QD beginning on day -7 and continuing until ANC are equal or over 1000. Patients also receive fludarabine phosphate IV over 30 minutes and approximately 4 hours later followed by cytarabine IV over 1 hour on days -6 to -2 (days -6 to -3 for patients over age 60). Beginning 2-7 days after the last dose of fludarabine phosphate and cytarabine, patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells IV over 30 minutes thrice weekly for 3 doses over 4 days (Monday-Thursday only).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (NK cells)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (NK cells)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim-sndz</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (NK cells)</arm_group_label>
    <other_name>Filgrastim Biosimilar Filgrastim-sndz</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (NK cells)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (NK cells)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (NK cells)</arm_group_label>
    <other_name>(mbIL21)-expanded Haploidentical NK Cells</other_name>
    <other_name>mbIL21-expanded Haploidentical NK Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed or primary refractory AML; patients with relapsed AML after
             allogeneic stem cell transplantation, including those who have received donor
             lymphocyte infusions, are eligible if they have no active graft versus host disease
             (GVHD) and are off immunosuppression

          -  Have a haploidentical family peripheral blood donor selected for best possible killer
             cell immunoglobulin-like receptor (KIR) reactivity; KIR typing will not be indicated
             if there is only one haploidentical donor; KIR typing is advised to be done if
             feasible and does not delay transplant

          -  Karnofsky or Lansky performance scale (PS) greater or equal to 70

          -  Serum creatinine =&lt; 2 mg/dl or creatinine clearance greater or equal than 40 cc/min;
             creatinine for pediatric patients =&lt; 2 mg/dl or =&lt; 2 times upper limit of normal for
             age (whichever is less)

          -  Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and diffusing
             capacity of the lungs for carbon monoxide (DLCO) &gt;= 50% of expected, corrected for
             hemoglobin; for pediatric patients, if unable to perform pulmonary function tests
             (most children &lt; 7 years of age), pulse oximetry &gt;= 92% on room air by pulse oximetry

          -  Total bilirubin =&lt; 2 mg/dl or =&lt; 2.5 x upper limit of normal (ULN) for age (unless
             Gilbert's syndrome)

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 2.5 x
             ULN for age

          -  Left ventricular ejection fraction &gt;= 40%; no uncontrolled arrhythmias or uncontrolled
             symptomatic cardiac disease

          -  Negative serum test to rule out pregnancy within 2 weeks prior to registration in
             females of childbearing potential (non-childbearing potential defined as premenarchal,
             greater than one year post-menopausal, or surgically sterilized)

          -  Sexually active males and females of childbearing potential must agree to use a form
             of contraception considered effective and medically acceptable by the investigator

          -  Negative serology for human immunodeficiency virus (HIV)

          -  DONOR: Donor must be 16 years of age or older and weigh at least 110 pounds

          -  DONOR: Donor must be a human leukocyte antigen (HLA)-haploidentical relative selected
             for best NK alloreactivity, defined as having a KIR gene present on the donor NK cells
             for which the relevant HLA haplotype (KIR ligand) is absent in the recipient and
             present in the donor or selected on the basis of activating KIR gene content

          -  DONOR: Donor must meet standard institutional eligibility and donor certification
             criteria for therapeutic cell product donation

          -  DONOR: Not be pregnant as defined by negative serum (beta human chorionic gonadotropin
             [beta HCG]) pregnancy test in females of childbearing potential (non-childbearing
             potential defined as premenarchal, previous surgical sterilization, or postmenopausal
             for &gt; 12 months)

          -  DONOR: Evaluation: history and physical examination; laboratory examinations:
             hematology, electrolytes, chemistry; infectious disease screening and serology; HLA
             typing; KIR typing will not be indicated if there is only one haploidentical donor;
             KIR typing is advised to be done if feasible and does not delay transplant

        Exclusion Criteria:

          -  Congestive heart failure &lt; 6 months prior to screening

          -  Unstable angina pectoris &lt; 6 months prior to screening

          -  Myocardial infarction &lt; 6 months prior to screening

          -  Uncontrolled infection, defined as an infection which has not resolved spontaneously
             or does not show evidence of significant resolution after initiating appropriate
             therapy, excluding chronic asymptomatic viral infections (e.g., human papillomavirus
             [HPV], BK virus, hepatitis C virus [HCV], etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan O Ciurea</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Ciurea</last_name>
    <phone>713-792-8750</phone>
    <email>sciurea@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan O. Ciurea</last_name>
      <phone>713-792-8750</phone>
    </contact>
    <investigator>
      <last_name>Stefan O. Ciurea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

